Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 2, 2014, Pages 72-79

  Castells Guitart, Mariana C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Desensitization; Drug hypersensitivity; IgE mediated; Monoclonal antibodies

Indexed keywords

ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOSPORIN; DOCETAXEL; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL;

CARDIOVASCULAR DISEASE; CHEMOTHERAPY; CHILL; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PROTOCOL; DESENSITIZATION; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA; FEVER; FLUSHING; HUMAN; INFLAMMATION; LIFE EXPECTANCY; MORBIDITY; PAIN; PRURITUS; QUALITY OF LIFE; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SERUM SICKNESS; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HEALTH CARE COSTS; HUMANS; PLATINUM; TAXOIDS;

EID: 84901922615     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Kadoyama K, Kuwahara A, Yamamori M, Brown JB, Sakaeda T, Okuno Y. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. J Exp Clin Cancer Res. 2011;30:93
2. Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y. Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2011;8:332-8.
3. Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol. 2006;6:476-81.
4. Solensky R. Drug hypersensitivity. Med Clin North Am. 2006;90:233-60.
5. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol. 2003;24:253-62.
6. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371-6.
7. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316:1622-6.
8. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26:451-63.
9. Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol. 2003;21:4611-4.
10. Caiado J, Venemalm L, Pereira-Santos MD, Costa L, Pereira Barbosa M, Castells M. Carboplatin-, Oxaliplatin-, and Cisplatin specific IgE: Cross-reactivity and Value in the Diagnosis of Carboplatin and Oxaliplatin Allergy. J Allergy Clin Immunol Pract. 2013;1:494-500.
11. Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol. 2003;111(2 Suppl):548-59.
12. Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs. 2014;28(2):133-44.
13. Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A, Campi P, Sanz ML, Castells M, Demoly P, Pichler WJ; European Network of Drug Allergy and the EAACI interest group on drug hypersensitivity. General considerations on rapid desensitization for drug hypersensitivity-a consensus statement. Allergy. 2010;65:1357-66.
14. Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgEmediated reactions. Gynecol Oncol. 2004;95:370-6.
15. Paolini R, Numerof R, Kinet JP. Phosphorylation / dephosphorylation of high affinity IgE receptors: a mechanism for coupling /uncoupling a large signaling complex. Proc Natl Acad Sci USA. 1992;89:10733-7.
16. Morales AR, Shah N, Castells M. Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol. 2005;94:575-80.
17. Sancho-Serra M, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FceRI internalization. Eur J Immunol. 2011;41:1004-13.
18. Oka T, Rios EJ, Tsai M, Kalesnikoff J, Galli SJ. Rapid desensitization induces internalization of antigen-specific IgE on mouse mast cells. J Allergy Clin Immunol. 2013;132:922-32.
19. Zhao W, Gomez G, Macey M, Kepley CL, Schwartz LB. In vitro desensitization of human skin mast cells. J Clin Immunol. 2012;32:150-60.
20. Castells M. Rapid Desensitization for Hypersensitivity Reactions to Medications. Immunol Allergy Clin North Am. 2009;29:585-606.
21. Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574-80.
22. Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, Gomez de Salazar E, Alvarez Cuesta E. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68:853-61.
23. Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Anton J, Espinos J, C Lacasa, M Fernández-Benítez, ML Sanz, M Ferrer. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol. 2011;21:108-12.
24. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-8.
25. Walker FE. Paclitaxel (TAXOL): side effects and patient education issues. Semin Oncol Nurs. 1993;9(4 Suppl 2):6-10.
26. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc. 2002;23:205-8.
27. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst. 1998;90:300-6.
28. Prieto García A, Pineda de la Losa F. Immunoglobulin E-Mediated Severe Anaphylaxis to Paclitaxel J Investig Allergol Clin Immunol. 2010;20: 170-6
29. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96:824-9.
30. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer. 2008;18:615-20.
31. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. doi:10.1155/2010/207084.
32. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J. Clinical Features of Hypersensitivity Reactions to Carboplatin. J Clin Oncol. 1999;17:1141-5.
33. Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53:121-2.
34. Thomas RR, Quinn mg, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer. 2003;97:2301-7.
35. Maindrault-Goebel F, André T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005;41:2262-7.
36. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009;123:1262-7 e1.
37. Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C, Giannopoulos A, Karatzas G, Giannikos L, Sfikakis PP. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001;61:129-33.
38. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84:378-82.
39. Lee CW, Matulonis UA, Castells MC. Rapid inpatient/ outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99:393-9.
40. Chung CH, O'Neil BH. Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors. Oncology (Williston Park). 2009;23:14-7.
41. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124:1259-66.
42. Breslow RG, Caiado J, Castells MC. Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009;102:155-60.